{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T13:53:16Z","timestamp":1782568396719,"version":"3.54.5"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc."},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000065","name":"NINDS","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000025","name":"NIMH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]},{"name":"International NeuroHIV Cure Consortium"},{"name":"Thai Government Pharmaceutical Organization"},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Efavirenz (EFV)- and dolutegravir (DTG)-based antiretroviral therapy (ART) is the former and current recommended regimen for treatment-naive individuals with human immunodeficiency virus type 1 (HIV-1). Whether they impact the immunological and neuropsychiatric profile differentially remains unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective analysis included 258 participants enrolled during acute HIV-1 infection (AHI). Participants initiated 1 of 3 ART regimens during AHI: EFV-based (n = 131), DTG-based (n = 92), or DTG intensified with maraviroc (DTG\/MVC, n = 35). All regimens included 2 nucleoside reverse-transcriptase inhibitors and were maintained for 96 weeks. CD4+ and CD8+ T-cell counts, mood symptoms, and composite score on a 4-test neuropsychological battery (NPZ-4) were compared.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At baseline, the median age was 26 years, 99% were male, and 36% were enrolled during Fiebig stage I\u2013II. Plasma viral suppression at weeks 24 and 96 was similar between the groups. Compared with the EFV group, the DTG group showed greater increments of CD4+ (P &amp;lt; .001) and CD8+ (P = .015) T-cell counts but a similar increment of CD4\/CD8 ratio at week 96. NPZ-4 improvement was similar between the 2 groups at week 24 but greater in the DTG group at week 96 (P = .005). Depressive mood and distress symptoms based on the Patient Health Questionnaire and distress thermometer were similar between the 2 groups at follow-up. Findings for the DTG\/MVC group were comparable to those for the DTG group vs the EFV group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Among individuals with AHI, 96 weeks of DTG-based ART was associated with greater increments of CD4+ and CD8+ T-cell counts and improvement in cognitive performance.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciac466","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T16:31:33Z","timestamp":1654878693000},"page":"e718-e726","source":"Crossref","is-referenced-by-count":11,"title":["Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection"],"prefix":"10.1093","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4071-4409","authenticated-orcid":false,"given":"Phillip","family":"Chan","sequence":"first","affiliation":[{"name":"South East Asia Research Collaboration in HIV, Institute of HIV Research and Innovation , Bangkok , Thailand"},{"name":"Department of Neurology, Yale School of Medicine , New Haven, Connecticut , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohyung","family":"Yoon","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research , Silver Spring, Maryland , USA"},{"name":"Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donn","family":"Colby","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research , Silver Spring, Maryland , USA"},{"name":"Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eug\u00e8ne","family":"Kroon","sequence":"additional","affiliation":[{"name":"South East Asia Research Collaboration in HIV, Institute of HIV Research and Innovation , Bangkok , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Sacdalan","sequence":"additional","affiliation":[{"name":"South East Asia Research Collaboration in HIV, Institute of HIV Research and Innovation , Bangkok , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somchai","family":"Sriplienchan","sequence":"additional","affiliation":[{"name":"South East Asia Research Collaboration in HIV, Institute of HIV Research and Innovation , Bangkok , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suteeraporn","family":"Pinyakorn","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research , Silver Spring, Maryland , USA"},{"name":"Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintanat","family":"Ananworanich","sequence":"additional","affiliation":[{"name":"Department of Global Health, Amsterdam University Medical Centers, Amsterdam Institute for Global Health and Development, University of Amsterdam , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Valcour","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memory and Aging Center, University of California\u2013San Francisco, San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Vasan","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research , Silver Spring, Maryland , USA"},{"name":"Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Hsu","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research , Silver Spring, Maryland , USA"},{"name":"Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nittaya","family":"Phanuphak","sequence":"additional","affiliation":[{"name":"South East Asia Research Collaboration in HIV, Institute of HIV Research and Innovation , Bangkok , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Paul","sequence":"additional","affiliation":[{"name":"Faculty of Psychological Sciences, Missouri Institute of Mental Health, University of Missouri-St. Louis , St. Louis, Missouri , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Spudich","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yale School of Medicine , New Haven, Connecticut , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"issue":"Suppl 3","key":"2023020817082916700_ciac466-B1","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1097\/QAD.0000000000002355","article-title":"Global, regional and country-level 90-90-90 estimates for 2018: assessing progress towards the 2020 target","volume":"33","author":"Marsh","year":"2019","journal-title":"AIDS"},{"key":"2023020817082916700_ciac466-B2","doi-asserted-by":"publisher","first-page":"101471","DOI":"10.1016\/j.smim.2021.101471","article-title":"Residual immune dysfunction under antiretroviral therapy","volume":"51","author":"Cai","year":"2021","journal-title":"Semin Immunol"},{"key":"2023020817082916700_ciac466-B3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11904-019-00421-0","article-title":"HIV, depression, and cognitive impairment in the era of effective antiretroviral therapy","volume":"16","author":"Rubin","year":"2019","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2023020817082916700_ciac466-B4","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s11481-019-09886-7","article-title":"CNS neurotoxicity of antiretrovirals","volume":"16","author":"Lanman","year":"2021","journal-title":"J Neuroimmune Pharmacol"},{"key":"2023020817082916700_ciac466-B5"},{"key":"2023020817082916700_ciac466-B6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1586\/14787210.2016.1157469","article-title":"A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications","volume":"14","author":"Gaida","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2023020817082916700_ciac466-B7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/15284336.2018.1511348","article-title":"Sleep and neuropsychological performance in HIV+ subjects on efavirenz-based therapy and response to switch in therapy","volume":"19","author":"Shikuma","year":"2018","journal-title":"HIV Clin Trials"},{"key":"2023020817082916700_ciac466-B8","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"2023020817082916700_ciac466-B9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/QAI.0000000000000790","article-title":"Brief report: dolutegravir plus abacavir\/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial","volume":"70","author":"Walmsley","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023020817082916700_ciac466-B10","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s12879-021-06016-8","article-title":"Correction to: comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naive patients infected with HIV-1: an update on a systematic review and network meta-analysis","volume":"21","author":"Nickel","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2023020817082916700_ciac466-B11","doi-asserted-by":"crossref","first-page":"ofaa340","DOI":"10.1093\/ofid\/ofaa340","article-title":"Do combination antiretroviral therapy regimens for HIV infection feature diverse T-cell phenotypes and inflammatory profiles?","volume":"7","author":"Tincati","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2023020817082916700_ciac466-B12"},{"key":"2023020817082916700_ciac466-B13","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/QAD.0000000000001459","article-title":"Neuropsychiatric adverse effects on dolutegravir: an emerging concern in Europe","volume":"31","author":"Menard","year":"2017","journal-title":"AIDS"},{"key":"2023020817082916700_ciac466-B14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/QAI.0000000000001269","article-title":"Psychiatric symptoms in patients receiving dolutegravir","volume":"74","author":"Fettiplace","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023020817082916700_ciac466-B15","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.cmi.2017.11.016","article-title":"Impact of dolutegravir and efavirenz on immune recovery markers: results from a randomized clinical trial","volume":"24","author":"Blanco","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2023020817082916700_ciac466-B16","doi-asserted-by":"crossref","first-page":"e588","DOI":"10.1016\/S2352-3018(18)30173-5","article-title":"HIV drug resistance in low-income and middle-income countries","volume":"5","author":"Hamers","year":"2018","journal-title":"Lancet HIV"},{"key":"2023020817082916700_ciac466-B17","doi-asserted-by":"crossref","first-page":"e25324","DOI":"10.1002\/jia2.25324","article-title":"Switch to dolutegravir is well tolerated in Thais with HIV infection","volume":"22","author":"Goh","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"2023020817082916700_ciac466-B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12981-019-0257-8","article-title":"Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort","volume":"17","author":"Chan","year":"2020","journal-title":"AIDS Res Ther"},{"key":"2023020817082916700_ciac466-B19","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1097\/00002030-200309050-00005","article-title":"Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection","volume":"17","author":"Fiebig","year":"2003","journal-title":"AIDS"},{"key":"2023020817082916700_ciac466-B20","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1093\/cid\/cix1063","article-title":"Acute retroviral syndrome is associated with high viral burden, CD4 depletion, and immune activation in systemic and tissue compartments","volume":"66","author":"Crowell","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2023020817082916700_ciac466-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13803395.2012.733682","article-title":"Development of normative neuropsychological performance in Thailand for the assessment of HIV-associated neurocognitive disorders","volume":"35","author":"Heaps","year":"2013","journal-title":"J Clin Exp Neuropsychol"},{"key":"2023020817082916700_ciac466-B22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-244X-8-46","article-title":"Reliability and validity of the Thai version of the PHQ-9","volume":"8","author":"Lotrakul","year":"2008","journal-title":"BMC Psychiatry"},{"key":"2023020817082916700_ciac466-B23","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/(SICI)1097-0142(19980515)82:10<1904::AID-CNCR13>3.0.CO;2-X","article-title":"Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study","volume":"82","author":"Roth","year":"1998","journal-title":"Cancer"},{"key":"2023020817082916700_ciac466-B24","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"key":"2023020817082916700_ciac466-B25","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/S2352-3018(15)00006-5","article-title":"CD4\/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study","volume":"2","author":"Mussini","year":"2015","journal-title":"Lancet HIV"},{"key":"2023020817082916700_ciac466-B26","doi-asserted-by":"crossref","first-page":"e105653","DOI":"10.1371\/journal.pone.0105653","article-title":"48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis","volume":"9","author":"Patel","year":"2014","journal-title":"PLoS One"},{"key":"2023020817082916700_ciac466-B27","doi-asserted-by":"crossref","first-page":"100573","DOI":"10.1016\/j.eclinm.2020.100573","article-title":"Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400 mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis","volume":"28","author":"Kanters","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2023020817082916700_ciac466-B28","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1001\/archinte.163.18.2187","article-title":"CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV cohort study","volume":"163","author":"Kaufmann","year":"2003","journal-title":"Arch Intern Med"},{"key":"2023020817082916700_ciac466-B29","doi-asserted-by":"crossref","first-page":"e565-e73","DOI":"10.1016\/S2352-3018(20)30202-2","article-title":"Effects of first-line antiretroviral therapy on the CD4\/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study","volume":"7","author":"Serrano-Villar","year":"2020","journal-title":"Lancet HIV"},{"key":"2023020817082916700_ciac466-B30","doi-asserted-by":"crossref","first-page":"21526","DOI":"10.7448\/IAS.20.1.21526","article-title":"Differential effects of antiretrovirals on microbial translocation and gut microbiota composition of HIV-infected patients","volume":"20","author":"Villanueva-Millan","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"2023020817082916700_ciac466-B31","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s10461-011-9939-5","article-title":"A systematic review of the psychiatric side-effects of efavirenz","volume":"15","author":"Kenedi","year":"2011","journal-title":"AIDS Behav"},{"key":"2023020817082916700_ciac466-B32","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/QAD.0000000000000538","article-title":"Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease?","volume":"29","author":"Underwood","year":"2015","journal-title":"AIDS"},{"key":"2023020817082916700_ciac466-B33","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/QAD.0000000000002236","article-title":"Altered neuropsychological performance and reduced brain volumetrics in people living with HIV on integrase strand transfer inhibitors","volume":"33","author":"O'Halloran","year":"2019","journal-title":"AIDS"},{"key":"2023020817082916700_ciac466-B34","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2020-002374","article-title":"Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study","author":"Fernandez-Bargiela","year":"2020","journal-title":"Eur J Hosp Pharm"},{"key":"2023020817082916700_ciac466-B35","doi-asserted-by":"publisher","first-page":"902","DOI":"10.3390\/cells8080902","article-title":"Deep sequencing reveals central nervous system compartmentalization in multiple transmitted\/founder virus acute HIV-1 infection","volume":"8","author":"Tovanabutra","year":"2019","journal-title":"Cells"},{"key":"2023020817082916700_ciac466-B36","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/QAD.0000000000002786","article-title":"Minimal detection of cerebrospinal fluid escape after initiation of antiretroviral therapy in acute HIV-1 infection","volume":"35","author":"Handoko","year":"2021","journal-title":"AIDS"},{"key":"2023020817082916700_ciac466-B37","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/QAD.0000000000000066","article-title":"Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection","volume":"28","author":"Puertas","year":"2014","journal-title":"AIDS"},{"key":"2023020817082916700_ciac466-B38","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/QAD.0000000000000951","article-title":"Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder","volume":"30","author":"Gates","year":"2016","journal-title":"AIDS"},{"key":"2023020817082916700_ciac466-B39","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1097\/QAD.0b013e3283389dfa","article-title":"Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study","volume":"24","author":"Palella FJ","year":"2010","journal-title":"AIDS"},{"key":"2023020817082916700_ciac466-B40","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1089\/aid.2012.0034","article-title":"Short communication: initiation of an abacavir-containing regimen in HIV-infected adults is associated with a smaller decrease in inflammation and endothelial activation markers compared to non-abacavir-containing regimens","volume":"28","author":"Hileman","year":"2012","journal-title":"AIDS Res Hum Retroviruses"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac466\/44817988\/ciac466.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/3\/e718\/49125226\/ciac466.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/3\/e718\/49125226\/ciac466.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T17:46:32Z","timestamp":1675878392000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/76\/3\/e718\/6605344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,6,10]]},"published-print":{"date-parts":[[2023,2,8]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac466","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,6,10]]}}}